On 25 October 2011, the WTO TRIPS Council held its annual review of the Paragraph 6 System under Item G. Under the sub-heading of alternatives to the Paragraph 6 system, Ecuador asked the European Union (EU) about the issuance of three compulsory licenses in Italy between 2005 to 2007. In its intervention, Ecuador asked the EU for more detail regarding the Italian Competition Authority’s issuance of compulsory licenses for export to Spain and other EU members in cases involving Glaxo and Merck including, but not limited to, administrative procedures, decision-making processes, and rationale. Continue Reading →
The ninth round of negotiations for the Trans-Pacific Partnership Agreement (TPPA) took place in Lima, Peru from 19-28 October 2011. Stakeholders were given the opportunity to present at the stakeholder platform on 23 October, attend the stakeholder briefing on 25 October and the reception on 25 October.
This is the intervention that the United States made on ACTA on 25 October 2011 during the WTO TRIPS Council discussions of “Enforcement of Intellectual Property Rights”.
O. ENFORCEMENT OF INTELLECTUAL PROPERTY RIGHTS (PARTY III OF THE TRIPS AGREEMENT)
The United States thanks Japan for its opening remarks, with which we fully associate ourselves.
We appreciate this opportunity to share with colleagues from other WTO Members our views on the importance of enforcement and to provide some additional information on the ACTA.
G. REVIEW UNDER PARAGRAPH 8 OF THE DECISION ON THE IMPLEMENTATION OF PARAGRAPH 6 OF THE DOHA DECLARATION ON THE TRIPS AGREEMENT AND PUBLIC HEALTH
We welcome the opportunity to participate in the annual review on the implementation of paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health.
OCTOBER TRIPS COUNCIL MEETING
October 24-25, 2011
Canada’s Intervention for Agenda Item G (Access to Medicines)
Mr. Chairman, Canada welcomes this opportunity to discuss the implementation of the Paragraph 6 system and to share some thoughts on the issue of access to medicines.
On Tuesday, 25 October 2011, Canada made the following intervention at the WTO TRIPS Council on ACTA under agenda item O, “Trends in Enforcement”.
In relation to the WTO Doha Declaration on the TRIPS Agreement and Public Health, Canada asserted the following,
ACTA is also consistent with the TRIPS Agreement and the Declaration on TRIPS and Public Health and will not hinder the cross-border transit of legitimate generic medicines.
Register of Copyrights Maria A. Pallante has made public the “priorities and special projects” of the US Copyright Office from October 2011 to October 2013. The ambitious work plan sets 17 priorities in the areas of copyright policy and administrative practices, and 10 special projects “to improve the quality and efficiency of the U.S. Copyright Office’s services.”
The 16 page document is available here
Comments should be sent to registerofcopyrights@copyright.gov
On 25 October 2011, India delivered the following intervention at the WTO TRIPS Council raising concerns on ACTA and the TPPA during discussions of “Trends in the Enforcement of Intellectual Property Rights”. On ACTA, India voiced concerns on the scope of ACTA’s civil enforcement measures, border measures potential role in the seizure of generic medicines, third party liability, damages and also raised systemic issues such as how WTO MFN obligations would affect WTO members who are not ACTA parties,
On 25 October 2011, the WTO TRIPS Council held its annual review of the Paragraph 6 System. The following are extracts from the intervention of India. Note that under “Any alternatives to the use of Paragraph 6 System to achieve the objective of access to medicines” India asked the United States to shed light on state practice in the US following the US Supreme Court’s eBay versus MercExchange ruling (/content/view/174/1). Continue Reading →
April 29, 2010. Brand name: Provenge
Generic name: Sipuleucel-T
Marketed by: Dendreon
Indication: therapy for certain men with advanced prostate cancer that uses their own immune system to fight the disease.
FDA press release here.
US Price: $31,000 per infusion. A full course of treatment is three infusions over a one-month period, or $93k. Continue Reading →